Geron (GERN) Upgraded at ValuEngine

ValuEngine upgraded shares of Geron (NASDAQ:GERN) from a hold rating to a buy rating in a report published on Wednesday morning.

Several other equities research analysts have also commented on the stock. BidaskClub lowered shares of Geron from a hold rating to a sell rating in a report on Wednesday, May 16th. Zacks Investment Research upgraded shares of Geron from a hold rating to a buy rating and set a $4.50 price target for the company in a report on Tuesday, April 24th. Piper Jaffray Companies restated a buy rating and issued a $7.00 price target on shares of Geron in a report on Monday, March 19th. Finally, Stifel Nicolaus boosted their price target on shares of Geron from $2.50 to $4.00 and gave the company a hold rating in a report on Sunday, March 18th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $5.17.

NASDAQ:GERN opened at $4.70 on Wednesday. Geron has a one year low of $1.74 and a one year high of $6.68. The stock has a market capitalization of $834.25 million, a PE ratio of -26.11 and a beta of 2.31.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. Geron had a negative net margin of 3,300.12% and a negative return on equity of 26.20%. The business had revenue of $0.32 million during the quarter. During the same quarter in the prior year, the firm posted ($0.05) EPS.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Deutsche Bank AG raised its stake in shares of Geron by 70.1% during the 4th quarter. Deutsche Bank AG now owns 696,410 shares of the biopharmaceutical company’s stock worth $1,251,000 after acquiring an additional 286,979 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of Geron during the 4th quarter worth approximately $481,000. Goldman Sachs Group Inc. raised its stake in shares of Geron by 97.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 238,143 shares of the biopharmaceutical company’s stock worth $429,000 after acquiring an additional 117,457 shares in the last quarter. Creative Planning raised its stake in shares of Geron by 69.8% during the 4th quarter. Creative Planning now owns 308,523 shares of the biopharmaceutical company’s stock worth $555,000 after acquiring an additional 126,810 shares in the last quarter. Finally, Virtus Fund Advisers LLC bought a new position in shares of Geron during the 4th quarter worth approximately $314,000. Hedge funds and other institutional investors own 34.46% of the company’s stock.

Geron Company Profile

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply